The Lumipulse G pTau217/β-Amyloid 1–42 Plasma Ratio is a blood test that measures two brain proteins—phosphorylated tau-217 and amyloid-beta-42—to detect Alzheimer's disease neuropathology in symptomatic adults aged 55 and older. FDA approved the test on May 16, 2025, making it the first blood-based biomarker cleared to support Alzheimer's diagnosis in patients with cognitive symptoms or suspected cognitive decline. The test is designed for people already showing signs of cognitive problems—not for screening healthy people—and works as part of a comprehensive diagnostic workup alongside cognitive testing, neurologic exam, and brain imaging. It is not a replacement for the full diagnostic process, but it can reduce the need for more invasive procedures like lumbar puncture or PET scanning.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the Test Measures and How It Works
- Who It Is For and Who It Is Not
- How Accurate Is the Test
- How It Fits Into Your Diagnostic Workup
- When Results Are Unclear and Plasma Limitations
What the Test Measures and How It Works
The Lumipulse test quantifies phospho-tau-217 and amyloid-beta-42 levels in blood plasma. Elevated phospho-tau-217 correlates with amyloid-β buildup in the brain—the hallmark pathology of Alzheimer's disease. The test reports results as a ratio: negative (≤0.185 pg/mL), intermediate (0.186–0.324), or positive (≥0.325).
A positive result suggests Alzheimer's disease neuropathology is present. The test uses a fully automated chemiluminescent enzyme immunoassay platform, which means it requires only a single blood draw and no lumbar puncture. Results are generated without subjective interpretation, reducing variability between laboratories. The entire process is straightforward from a patient perspective: one needle stick, one sample.
Who It Is For and Who It Is Not
The FDA cleared Lumipulse for adults aged 55 and older who are experiencing cognitive symptoms or have objective cognitive impairment. This includes people with mild cognitive impairment (MCI) or those with clinical suspicion of Alzheimer's disease but not yet diagnosed.
It is not approved for screening asymptomatic people or those with normal cognition—even if they are anxious about memory or family history. The test's primary real-world use is confirming amyloid pathology in candidates for disease-modifying therapies like lecanemab (Leqembi), anti-amyloid monoclonal antibodies that can slow cognitive decline if given early in the disease course. If you are considering these drugs, the test may help your doctor establish whether amyloid pathology justifies the cost, side-effect risk, and monitoring burden.
How Accurate Is the Test
Clinical studies show 92% sensitivity and 96% specificity for plasma pTau217. In plain language: if you have Alzheimer's disease neuropathology, the test is likely to detect it; if you do not, the test is likely to come back negative.
In one study of 499 plasma samples, 91.7% of positive results aligned with amyloid pathology confirmed by PET imaging or cerebrospinal fluid (CSF) testing, and 97.3% of negative results ruled out amyloid pathology. This accuracy is stronger than older plasma biomarkers like phospho-tau181 or the amyloid-beta 42/40 ratio, and it performs well even in preclinical and mild cognitive impairment stages—stages where early intervention may have the most impact.
How It Fits Into Your Diagnostic Workup
The Lumipulse test is one piece of diagnosis, not the whole picture. FDA guidance and clinical research emphasize that the test must be paired with cognitive testing, a neurologic examination, neuropsychological assessment, and brain imaging (MRI or PET). The test replaces the need for invasive cerebrospinal fluid testing via lumbar puncture but does not replace the full diagnostic evaluation.
Your doctor will order this test if you have cognitive symptoms and they suspect Alzheimer's disease. A positive result supports that diagnosis; a negative result argues against amyloid pathology and suggests another cause for cognitive decline (e.g., vascular dementia, Lewy body disease, frontotemporal dementia, or depression). The test narrows the diagnostic path but does not stand alone.
When Results Are Unclear and Plasma Limitations
About 20% of tests yield intermediate results, which require repeat testing or follow-up imaging for clarity. Additionally, amyloid-beta isoforms show greater variation between blood plasma and cerebrospinal fluid, meaning some people may have conflicting plasma and CSF results.
This is a known caveat in the field and does not invalidate the test, but it means an intermediate or discordant result is not automatically definitive. If your result falls in the ambiguous middle range, your doctor may recommend repeating the test after a few months, ordering PET imaging, or both. Intermediate results are not a failure of the test; they reflect the biology of amyloid markers in blood, which is more variable than markers in cerebrospinal fluid.
